Samanta Kisele

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 10

Top Topics

Top Venues

Molecular cancer therapeutics

Science advances

Cancer research

This page only lists publications with an associated author ORCID identifier.

Publications

Sara G Danielli, Jakob Wurth, Sarah Morice, Samanta Kisele, Didier Surdez, Olivier O Delattre, Peter Karl Bode, Marco Wachtel, Beat W Schäfer
Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer. Molecular cancer therapeutics 23 (6) (2024)
Sara G Danielli, Jakob Wurth, Sarah Morice, Samanta Kisele, Didier Surdez, Olivier O Delattre, Peter Karl Bode, Marco Wachtel, Beat W Schäfer
Evaluation of the role of AXL in fusion-positive pediatric rhabdomyosarcoma identifies the small-molecule inhibitor bemcentinib (BGB324) as potent chemosensitizer. Molecular cancer therapeutics (2024)
Sara G Danielli, Jakob Wurth, Sarah Morice, Samanta Kisele, Didier Surdez, Olivier O Delattre, Peter Karl Bode, Marco Wachtel, Beat W Schäfer
Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer. Molecular cancer therapeutics 23 (6) (2024)
Sara G Danielli, Jakob Wurth, Sarah Morice, Samanta Kisele, Didier Surdez, Olivier O Delattre, Peter Karl Bode, Marco Wachtel, Beat W Schäfer
Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer. Molecular cancer therapeutics 23 (6) (2024)
Sara G Danielli, Jakob Wurth, Sarah Morice, Samanta Kisele, Didier Surdez, Olivier O Delattre, Peter Karl Bode, Marco Wachtel, Beat W Schäfer
Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer. Molecular cancer therapeutics 23 (6) (2024)
Joana G Marques, Blaz Pavlovic, Quy A Ngo, Gloria Pedot, Michaela Roemmele, Larissa Volken, Samanta Kisele, Romain Perbet, Marco Wachtel, Beat W Schäfer
The chromatin remodeler CHD4 sustains Ewing Sarcoma cell survival by controlling global chromatin architecture. Cancer research (2023)
Sara G Danielli, Ermelinda Porpiglia, Andrea J De Micheli, Natalia Navarro, Michael J Zellinger, Ingrid Bechtold, Samanta Kisele, Larissa Volken, Joana G Marques, Stephanie Kasper, Peter Karl Bode, Anton G Henssen, Dennis Gurgen, Olivier Delattre, Didier Surdez, Josep Roma, Peter Bühlmann, Helen M Blau, Marco Wachtel, Beat W Schäfer
Single-cell profiling of alveolar rhabdomyosarcoma reveals RAS pathway inhibitors as cell-fate hijackers with therapeutic relevance. Science advances 9 (6) (2023)
Sara G Danielli, Ermelinda Porpiglia, Andrea J De Micheli, Natalia Navarro, Michael J Zellinger, Ingrid Bechtold, Samanta Kisele, Larissa Volken, Joana G Marques, Stephanie Kasper, Peter Karl Bode, Anton G Henssen, Dennis Gurgen, Olivier Delattre, Didier Surdez, Josep Roma, Peter Bühlmann, Helen M Blau, Marco Wachtel, Beat W Schäfer
Single-cell profiling of alveolar rhabdomyosarcoma reveals RAS pathway inhibitors as cell-fate hijackers with therapeutic relevance. Science advances 9 (6) (2023)
Sara G Danielli, Ermelinda Porpiglia, Andrea J De Micheli, Natalia Navarro, Michael J Zellinger, Ingrid Bechtold, Samanta Kisele, Larissa Volken, Joana G Marques, Stephanie Kasper, Peter Karl Bode, Anton G Henssen, Dennis Gurgen, Olivier Delattre, Didier Surdez, Josep Roma, Peter Bühlmann, Helen M Blau, Marco Wachtel, Beat W Schäfer
Single-cell profiling of alveolar rhabdomyosarcoma reveals RAS pathway inhibitors as cell-fate hijackers with therapeutic relevance. Science advances 9 (6) (2023)
Sara G Danielli, Ermelinda Porpiglia, Andrea J De Micheli, Natalia Navarro, Michael J Zellinger, Ingrid Bechtold, Samanta Kisele, Larissa Volken, Joana G Marques, Stephanie Kasper, Peter Karl Bode, Anton G Henssen, Dennis Gurgen, Olivier Delattre, Didier Surdez, Josep Roma, Peter Bühlmann, Helen M Blau, Marco Wachtel, Beat W Schäfer
Single-cell profiling of alveolar rhabdomyosarcoma reveals RAS pathway inhibitors as cell-fate hijackers with therapeutic relevance. Science advances 9 (6) (2023)